Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122929 | 0.84 | SUV39H2 (0.38) | SUV39H2CYP3A4POLBALDH1A1EPHX2 | |
| SCHEMBL9756597 | 0.78 | RORC (0.56) | CYP3A4POLBALDH1A1EPHX2EPHX1 | |
| SCHEMBL14756781 | 0.78 | KLF10 (0.37) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL4833160 | 0.76 | TRPV1 (0.33) | CYP3A4ALDH1A1EPHX2TSHR | |
| SCHEMBL20684953 | 0.76 | TP53 (0.35) | CYP3A4ALDH1A1 | |
| SCHEMBL14267851 | 0.76 | SUV39H2 (0.39) | SUV39H2CYP3A4ALDH1A1LMNA | |
| SCHEMBL23864401 | 0.76 | CTRC (0.41) | CYP3A4ALDH1A1EPHX2LMNATSHR | |
| SCHEMBL4515109 | 0.76 | EPHX1 (0.47) | CYP3A4POLBEPHX2EPHX1LMNA | |
| SCHEMBL7867235 | 0.73 | KLF10 (0.50) | CYP3A4LMNATSHR | |
| SCHEMBL11436568 | 0.73 | IDO1 (0.39) | SUV39H2CYP3A4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-1966222-A2 | PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007059341-A2 | PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059341-A2 | PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | MAP4K2, MAP4K5, MAP4K3 | SUV39H2 3037/4885CYP3A4 2211/4885POLB 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.